Recent news on Interferon Alfa 2B

International panel issues new HIV/HCV co-infection guidelines  -  May 24, 2007
Aidsmap,...for HCV mono-infected patients: 180 mcg/week of pegylated interferon alfa-2a (Pegasys) or 1.5 mcg/kg/week of pegylated interferon alfa-2b (PegIntron).

Committee for Medicinal Products for Human Use Post-authorisation ...  -  Apr 27, 2007
PharmaLive.com (press release),Please refer also to the peginterferon alfa-2b or interferon alfa-2b Summary of Product Characteristics (SPC) for prescribing information particular to that

Schering-Plough Announces Hepatitis C Data Presentations at ...  -  May 18, 2007
PR Newswire (press release),PEGINTRON There are no new adverse events specific to PEGINTRON as compared to INTRON(R) A (Interferon alfa-2b, recombinant) for Injection; however,

Schering-Plough Addresses Major Milestones and Challenges in ...  -  Apr 11, 2007
PharmaLive.com (press release),A Pegylated Interferon Alfa-2b Dose Reduction in HCV 1B Patients with Rapid Viral Response Does Not Affect Sustained Virological Response. Napoli, N. et al.

PEGINTRON(TM) Approved In China For Treating Chronic Hepatitis B  -  Apr 8, 2007
Medical News Today (press release),There are no new adverse events specific to PEGINTRON as compared to INTRON A (Interferon alfa-2b, recombinant) for Injection; however, the incidence of

Additional Preclinical Data Presented on Valopicitabine Combined ...  -  Apr 12, 2007
PR Newswire (press release),2 Manns, M. Peginterferon Alfa-2b Plus Ribavirin Compared with Interferon Alfa-2b Plus Ribavirin for Initial Treatment of Chronic Hepatitis C: A Randomized

ViroPharma Announces Presentation of Additional HCV-796 Data at ...  -  Apr 14, 2007
PipelineReview.com (press release),These data on the antiviral activity and tolerability of twice daily HCV-796 in combination with pegylated interferon alfa-2b (peg-IFN) elaborate on

Viropharma: hepatitis-C treatment more effective in combination  -  Apr 13, 2007
MarketWatch...that the HCV-796 compound was more effective in combination with pegylated interferon alfa-2b than when either of the drugs was administered alone.

Biotech In Review: Dyax Jumps On Positive Data  -  Apr 15, 2007
Seeking Alpha,The test showed that a combination of HCV-796 and pegylated interferon alfa-2b was more effective than either drug alone. The trial was conducted in

Valeant Pharmaceuticals Initiates Taribavirin Phase 2b Clinical Study  -  Mar 15, 2007
PharmaLive.com (press release),There also will be a control group comprised of ribavirin (800/1000/1200/1400 mg daily) and pegylated interferon alfa-2b. "Our analysis of the VISER studies

Case 2-2007 — A 49-Year-Old Woman with a Pigmented Lesion on the Arm  -  Jan 17, 2007
New England Journal of Medicine (subscription),35 Treatment with interferon alfa-2b at the maximal tolerated dose for 1 year 36 (20 million IU per square meter of body-surface area given intravenously 5

FDA Safety Changes: Keppra, Naropin, Rebetol  -  Dec 22, 2006
Medscape (subscription)In addition, dry mouth from long-term treatment with ribavirin and interferon alfa-2b or pegylated interferon alfa-2b can damage a patient's teeth and oral

FDA Safety Changes: Keppra, Naropin, Rebetol  -  Dec 22, 2006
Medscape (subscription)In addition, dry mouth from long-term treatment with ribavirin and interferon alfa-2b or pegylated interferon alfa-2b can damage a patient's teeth and oral

Clinical Advances in Hepatitis B and Hepatitis C  -  Dec 6, 2006
Medscape (subscription)There are 6 therapies currently approved by the US Food and Drug Administration (FDA) for the treatment of hepatitis B in adults: interferon alfa-2b;

New Data from Largest US Hepatitis C Trial Provide Insights Into ...  Oct 31, 2006
Pegylated interferon alfa-2b + ribavirin is equally efficacious and well tolerated in patients >65 years old in comparison to other age groups: subanalysis of ... -DG News Standard Therapy Has Similar Efficacy and Safety in Elderly ...  Nov 3, 2006
3, 2006 -- Elderly patients with chronic hepatitis C virus (HCV) who are treated with a standard regimen of pegylated interferon alfa-2b plus ribavirin have ... -DG News Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating ...  Oct 27, 2006
There are no new adverse events specific to PEG-INTRON as compared to INTRON® A (interferon alfa-2b, recombinant) for Injection, however, the incidence of ... -Yahoo! News (press release) Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating ...  Oct 27, 2006
PEG-INTRON There are no new adverse events specific to PEG-INTRON as compared to INTRON(R) A (interferon alfa-2b, recombinant) for Injection, however, the ... -PR Newswire (press release), Sustained Virological Response Achieved With Weight-Based ...  Nov 1, 2006
...chronic hepatitis C virus (HCV) genotype 2 appear to have excellent sustained virologic responses (SVR) to a combination of pegylated interferon alfa-2b 1.5 mcg ... -DG News Pharma Sector: Few Newsmakers Of The Week - Novartis, Abbott ...  Oct 28, 2006
HB (lamivudine), Gilead Sciences' Hepsera (adefovir), Bristol-Myers Squibb's Baraclude (entecavir), Schering Corp.'s Intron A (interferon alfa-2b) and Roche's ... -Trading Markets, ViroPharma And Wyeth Initiate Dosing In Phase 2 Study Of HCV-796 ...  Oct 25, 2006
...the safety, tolerability, pharmacokinetic profile, and antiviral activity of HCV-796, when used in combination with pegylated interferon alfa-2b plus ribavirin ... -Medical News Today (press release), ViroPharma Announces Positive Data from Phase 1b Combination Study ...  Aug 28, 2006
...data are available in the dose range of 100 mg BID to 1,000 mg BID of HCV-796 dosed over a 14-day period in combination with pegylated interferon alfa-2b. ... -Yahoo! News

Ahead of the Bell: ViroPharma Rises  Aug 29, 2006
In the early trial, doses of the drug candidate, HCV-796, were combined with another hepatitis C treatment, pegylated interferon alfa-2b. ... -Houston Chronicle

ViroPharma Drug Promising in Early Trial  Aug 28, 2006
Wyeth. The doses, given orally in a Phase 1b study, were combined with pegylated interferon alfa-2b, another hepatitis C treatment. ... -Houston Chronicle

Clinical Advances in Hepatitis B and Hepatitis C  -  Dec 6, 2006
Medscape (subscription)There are 6 therapies currently approved by the US Food and Drug Administration (FDA) for the treatment of hepatitis B in adults: interferon alfa-2b;

Ahead of the Bell: ViroPharma Rises  29 Aug 2006
In the early trial, doses of the drug candidate, HCV-796, were combined with another hepatitis C treatment, pegylated interferon alfa-2b. ... -Houston Chronicle

Temodar® and Peg-Intron® Active in Metastatic Melanoma  Jul 27, 2006
Sloan-Kettering Cancer Center have reported that the combination of Temodar (temozolomide) and Peg-Intron (pegylated interferon-alfa 2b) has significant anti ... -Cancer Consultants

Pegylated Interferon Aids in Post-Transplant HCV  Jul 10, 2006
One third of patients treated with either standard Intron A (interferon alfa-2b) plus Rebetol, or Rebetol plus a pegylated interferon -- either Pegasys ... -MedPage Today

Jonathan R. Spicehandler, MD Retires From Schering-Plough  Jun 30, 2006
Plough, Dr. Spicehandler oversaw the development of some of the company's most significant products, including INTRON® A (interferon alfa-2b recombinant), an ... -Yahoo! News



EU Label Change for Intron A (Interferon Alfa-2b) Incorporates ...  Apr 26, 2006
Corporation today reported that the European Commission has adopted changes to the European Union (EU) label for Intron(R) A (interferon alfa-2b) based on long ... - DG News

EU Label Change for INTRON(R) A (interferon Alfa-2b) Incorporates ...  Apr 25, 2006
NYSE: SGP - News) today reported that the European Commission has adopted changes to the European Union (EU) label for INTRON® A (interferon alfa-2b) based on ... - Yahoo! News

Human Genome Sciences Presents Interim Results of Phase 2b Trial ...  May 1, 2006
Liver (EASL) in an oral presentation entitled "Interim (Week 12) Phase 2b Virological Efficacy and Safety Results of Albumin Interferon Alfa-2b Combined with ... - PR Newswire

- Interim results to date demonstrate Albuferon is safe, well ...  May 1, 2006
Association for the Study of the Liver (EASL) in an oral presentation entitled "A Phase 2 Dose-Escalation Study of Albumin Interferon Alfa-2b Combined with ... - Yahoo! News

Schering-Plough's Intron A gets EU label change  Apr 27, 2006
...that sustained loss of serum hepatitis C virus (HCV) RNA six months following the completion of treatment with nonpegylated interferon alfa-2b (with or without ... - Pharmaceutical Business Review

Lilly and Alkermes Initiate Additional Phase 3 Study and Merck ...  Apr 27, 2006
NYSE: SGP) recently reported that the European Commission has adopted changes to the European Union (EU) label for INTRON® A (interferon alfa-2b) based on long ... - Financial News USA





Industrial automation system saves costs  11 Apr 2006
System 800xA include: * Schering Plough chose ABB's System 800xA when it upgraded its facility in Cork, Ireland, that produced Interferon alfa-2b for the ... - Manufacturing Talk

Human Genome Sciences Announces Positive Interim Results of Phase ...  Mar 14, 2006
Interim (week 12) Phase 2b virological efficacy and safety results of albumin interferon alfa-2b combined with ribavirin in genotype 1 chronic hepatitis C ... - PR Newswire

Idenix Announces Thirteen Data Presentations at the 2006 European ...  Mar 17, 2006
Dr. Xiao-Jian Zhou, Idenix's Associate Director, Clinical Pharmacology, will present "Absence of Effect of Pegylated Interferon Alfa-2b on the Pharmacokinetics ... - PR Newswire

SP rises on deal and analyst upgrades  Mar 21, 2006
...since the demise of Rebetol (ribavirin) to generic competition and with increasing rivalry seen for its newer offering Peg-Intron (peg-interferon alfa 2b). ... - Pharma Times (subscription)



Healthcare: At a Glance - Roche Hepatitis Drug Thrust Onto Front ...  Mar 3, 2006
GlaxoSmithKline's Epivir (lamivudine) is the best-known product in this disease area, although Schering-Plough's Intron A (interferon alfa-2b) is also used to ... - International News Service,

Autoimmunity Suggests Better Response to Interferon for Melanoma  Feb 17, 2006
NEW YORK FEB 16, 2006 (Reuters Health) - Autoimmunity during treatment of melanoma with interferon alfa-2b signals longer relapse-free and overall survival ... - Cancerpage.com,

New Treatment Combination Effective for Chronic Hepatitis C  Feb 9, 2006
Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology. ... - AAP Grand Rounds (subscription)

Prognostic Significance of Autoimmunity during Treatment of ...  Feb 15, 2006
...the prognostic significance of autoimmunity in patients with stage IIB, IIC, or III melanoma who were treated with high-dose adjuvant interferon alfa-2b. ... - New England Journal of Medicine (subscription),

Combination of Chemotherapy and Immunotherapy Active Against ...  Jan 27, 2006
...excluded. Patients were treated with temozolomide, cisplatin, vinblastine, interleukin-2, and interferon alfa-2b. (Temozolomide ... - Cancer Consultants

Schering-Plough Reports FDA Grants Fast Track Designation to Oral ...  Jan 31, 2006
There are no new adverse events specific to PEG-Intron as compared to INTRON(R) A (interferon alfa-2b, recombinant) for Injection, however, the incidence of ... - DG News

Schering-Plough Reports FDA Grants Fast Track Designation to Oral ...  Jan 30, 2006
PEG-INTRON There are no new adverse events specific to PEG-INTRON as compared to INTRON(R) A (interferon alfa-2b, recombinant) for Injection, however, the ... - PR Newswire

Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in ...  Jan 12, 2006
PEG-INTRON, recombinant interferon alfa-2b linked to a 12,000 dalton polyethylene glycol (PEG) molecule, is a once-weekly therapy dosed according to patient ... - PR Newswire

Fatigue may be misdiagnosed as depression during anti-HCV therapy ...  Jan 23, 2006
...of anaemia and neutropenia (comparing dose reduction versus growth factor supplementation) in individuals receiving pegylated interferon alfa-2b (Viraferon-Peg ... - Aidsmap

Schering-Plough Initiates PEGINTRON(R) Maintenance Study in ...  Jan 12, 2006
PEGINTRON, recombinant interferon alfa-2b linked to a 12,000 dalton polyethylene glycol (PEG) molecule, is a once-weekly therapy dosed according to patient ... - PR Newswire UK

Schering-Plough swings to profit in Q4  Jan 31, 2006
Turnover was led by strong performances by: Peg-Intron (pegylated interferon alfa-2b plus ribavirin), for the treatment of hepatitis C, leaping 55% to $214 ... - Pharma Times (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional